SG3 Management’s Foghorn Therapeutics FHTX Stock Holding History

SG3 Management’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,000	Closed	-$114K	–	1100
2021 Q4	$114K	Buy	+5,000	New	+$71.9K	﹤0.01%	890

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SG3 Management's FHTX Position: Q1 2022 in Review

SG3 Management sold out of Foghorn Therapeutics (FHTX) in Q1 2022, closing a stake of 5,000 shares — an estimated $114K sold.

SG3 Management first reported a position in FHTX in Q4 2021 and held it in 1 quarter. The position peaked at $114K in Q4 2021. 61 funds tracked by Wall St. Rank hold FHTX as of Q1 2022.

SG3 Management reported no remaining Foghorn Therapeutics position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 5,000 Foghorn Therapeutics shares in Q1 2022, an estimated $114K.
SG3 Management first reported a position in Foghorn Therapeutics in Q4 2021 and held it in 1 quarter.
SG3 Management's Foghorn Therapeutics position peaked at $114K in Q4 2021.
61 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.